Spravato (esketamine nasal spray) represents a paradigm shift in depression treatment—the first FDA-approved rapid-acting antidepressant for treatment-resistant depression. While traditional antidepressants take weeks to work, Spravato produces symptom relief within hours or days. For patients failing multiple standard treatments, understanding Spravato's role versus traditional antidepressants is crucial.
What Is Treatment-Resistant Depression?
Treatment-resistant depression is major depression failing to respond to at least two adequate trials of different antidepressants at therapeutic doses for sufficient duration. Approximately 30% of depressed patients don't respond to standard medications despite proper dosing and timing. For these patients, Spravato offers a novel approach when traditional antidepressants have failed.
Spravato: The Ketamine Revolution
Spravato is the S-enantiomer of ketamine, an anesthetic that produces rapid antidepressant effects through NMDA receptor antagonism—a completely different mechanism from traditional serotonin-based medications. Administered as a nasal spray twice weekly for the first month, then weekly or bi-weekly, Spravato produces measurable symptom improvement within 24 hours in many patients. For treatment-resistant cases failing SSRIs, SNRIs, and other standard agents, Spravato provides hope where traditional medications failed.
Mechanism: Rapid vs. Slow
Traditional antidepressants work through serotonin modulation—a slow process requiring weeks for therapeutic effect. Spravato's NMDA antagonism activates rapid antidepressant cascades, producing brain-derived neurotrophic factor (BDNF) release and neuroplasticity within hours. This fundamental mechanism difference explains why Spravato works when traditional medications fail—it targets completely different brain pathways.
Efficacy for Treatment-Resistant Depression
Clinical trials demonstrate 50-70% response rates in treatment-resistant depression with Spravato, compared to much lower rates with additional antidepressant trials. For patients with multiple failed antidepressant attempts, Spravato offers substantially higher efficacy than adding another SSRI or SNRI. Onset is measured in days rather than weeks, providing rapid relief for severe, debilitating depression.
Speed of Response
Spravato produces measurable improvement within 24 hours in many patients, with fuller response over days to weeks. Traditional antidepressants require 4-6 weeks minimum for therapeutic effect. For suicidal patients or those with severe functional impairment, Spravato's rapid onset can be life-saving. This speed advantage makes Spravato particularly valuable for acute, severe depression.
Administration and Monitoring
Spravato requires supervised in-clinic administration—patients receive the nasal spray in a healthcare setting and are monitored for 2 hours afterward. This contrasts sharply with traditional oral antidepressants taken at home. The supervised setting allows careful monitoring for dissociation and safety. However, this requirement adds time and logistical complexity compared to oral medications.
Dissociation and Side Effects
Spravato commonly causes dissociation—a temporary feeling of detachment or altered perception—during and immediately after administration. Most dissociative effects resolve within 2 hours. Blood pressure elevation occurs in some patients. Abuse potential exists due to ketamine's recreational properties, though Spravato's nasal formulation and supervised administration mitigate this risk. Traditional antidepressants lack dissociation but carry different side effect profiles.
Combination with Traditional Antidepressants
Most patients receiving Spravato continue traditional antidepressants simultaneously. Spravato provides rapid acute relief while underlying antidepressant therapy addresses long-term maintenance. This combination approach provides faster response than antidepressant monotherapy while maintaining long-term symptom control. Spravato isn't typically used as a standalone medication but as a breakthrough treatment alongside traditional therapy.
Cost and Insurance Coverage
Spravato is expensive, often costing thousands of dollars for initial treatment courses. Insurance typically requires documentation of treatment-resistant depression (failed trials of multiple medications) before covering it. Traditional antidepressants, particularly generics, are far less expensive. Cost and insurance approval represent significant barriers to Spravato access.
Long-Term Outcomes
Research on Spravato's long-term efficacy is still developing. Initial rapid response is clear, but maintaining benefit requires ongoing Spravato doses. Some patients achieve remission and eventually taper successfully; others require indefinite maintenance therapy. Traditional antidepressants, once effective, often maintain benefit with continuous dosing. Long-term trajectory differs between Spravato's intermittent dosing and traditional daily antidepressants.
When Spravato Is Appropriate
Spravato is reserved for treatment-resistant depression—failure of at least two adequate antidepressant trials. It's not a first-line option and shouldn't replace trying traditional medications. For patients with severe, debilitating depression failing standard treatment, particularly those with suicidal ideation, Spravato offers rapid relief when traditional medications have failed. Your psychiatrist will assess whether your situation warrants Spravato.
Which Should You Choose?
Try traditional antidepressants first—they're effective for most patients and far simpler to manage. Consider Spravato only after failing adequate trials of traditional medications. If you have severe depression with suicidal thoughts unresponsive to standard treatment, discuss Spravato with your psychiatrist. The treatment path typically starts with traditional antidepressants and progresses to Spravato only if necessary.
Frequently Asked Questions
Is Spravato the same as ketamine?
Spravato is esketamine, the S-enantiomer of ketamine. They're related but not identical. Spravato is FDA-approved, pharmaceutical-grade, administered under medical supervision. Ketamine infusions exist informally but lack FDA approval for depression treatment. Spravato offers medical-grade rapid-acting antidepressant treatment.
Can I abuse Spravato like ketamine?
Abuse potential exists theoretically, but Spravato's in-clinic administration, medical supervision, and nasal formulation reduce risk substantially. Patients aren't given doses to take home; they receive supervised treatment in healthcare settings. This medical framework greatly reduces abuse potential compared to recreational ketamine.
How long does Spravato treatment take?
Initial intensive treatment involves twice-weekly nasal spray doses for 4 weeks, then weekly or bi-weekly doses during maintenance. Each in-clinic visit takes 2-3 hours including monitoring. Most patients show symptom improvement within days to weeks, much faster than traditional antidepressants. Long-term treatment duration varies by individual response.
When to See a Psychiatrist
If depression hasn't responded to adequate trials of multiple antidepressants, or if you're experiencing severe, treatment-resistant depression with suicidal thoughts, a psychiatric evaluation can determine if Spravato or other advanced treatments are appropriate for your situation.
Talk to Next Step Psychiatry
At Next Step Psychiatry in Lilburn, GA, Dr. Aneel Ursani and Fathima Chowdhury, PA-C understand treatment-resistant depression and contemporary treatment options including Spravato. Whether you need traditional antidepressants, Spravato, combination therapy, or other approaches, we'll work with you to achieve remission from depression.
4145 Lawrenceville Hwy STE 100, Lilburn, GA 30047 • 678-437-1659 • Schedule an appointment
This article is for informational purposes only and should not replace a consultation with a licensed mental health professional. Always consult with your psychiatrist before starting, stopping, or switching medications.